KIF1A

MAY 24, 2023

In this blog post, KIF1A.ORG Chief Science Officer Dr. Dominique Lessard describes a unique cross disciplinary experience with multiple scientific stakeholders in the rare disease space, all focused around our holistic understanding of KAND. Shi was designed to introduce and engage students in the process of scientific research and inquiry.

Disease 98

Disease Laboratories Research Science 98

The Pharma Data

JUNE 7, 2023

FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Source link: [link]

FDA Approval 40

FDA Approval FDA Disease Research Laboratories 40

Conversations in Drug Development Trends

DECEMBER 12, 2022

Genetic testing provides patients with a diagnosis for their illness, helps patients and family members to understand risks of developing new diseases, and can be used to support clinical trial advancement. What is the difference between a Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory vs a research laboratory?

Clinical Trials 52

Clinical Trials Trials Laboratories Research Laboratories 52

The Pharma Data

JUNE 25, 2021

First-Time Disease-Free Survival Data to be Presented During Plenary Session at the 2021 ASCO Annual Meeting. 41.5), KEYTRUDA demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death by 32% compared to placebo (HR=0.68 [95% CI, 0.53–0.87]; KENILWORTH, N.J.–(BUSINESS

Disease 52

Disease Therapies Treatment Medical Schools 52

The Pharma Data

MARCH 23, 2022

Baynes, head of Global Clinical Development (GCD) and Chief Medical Officer, Merck Research Laboratories (MRL), will be retiring from Merck in July. Li, president, Merck Research Laboratories, until his retirement. Dr. Baynes will be succeeded by Dr. Eliav Barr, effective April 1, 2022.

Clinical Development 52

Clinical Development Vaccine Research Laboratories Laboratories 52

The Pharma Data

SEPTEMBER 11, 2020

The condition “is difficult to treat and the underlying drivers and natural history of the disease are not fully established,” noted Professor Claus Bachert, head of the Department of Oto-Rhino-Laryngology and chair of the Upper Airway Research Laboratory, University Hospital Ghent, Belgium, the principal investigator of the trial.

Research Laboratories 52

Research Laboratories Laboratories Treatment Hospitals 52

The Pharma Data

SEPTEMBER 21, 2020

First-line treatments for patients with ovarian cancer are designed to delay the disease’s progression for as long as possible to help achieve long-term remission. The PAOLA-1 trial showed that the combination of Lynparza with bevacizumab as a maintenance treatment reduced the risk of disease progression or death by 67%.

Research Laboratories 52

Research Laboratories Treatment Trials Laboratories 52

The Pharma Data

MARCH 13, 2021

Further, prespecified exploratory analyses showed donanemab slowed the accumulation of tau across key brain regions in patients affected by Alzheimer’s disease. Lilly’s chief scientific officer and president of Lilly Research Laboratories. Apostolova, M.D.,

Disease 40

Disease Trials Treatment Medical Schools 40

The Pharma Data

AUGUST 15, 2021

WELIREG Approved for Adult Patients With VHL Disease Who Require Therapy for Associated Renal Cell Carcinoma, Central Nervous System Hemangioblastomas, or Pancreatic Neuroendocrine Tumors, Not Requiring Immediate Surgery. The recommended dose of WELIREG (40 mg tablets) is 120 mg once daily until disease progression or unacceptance toxicity.

Treatment 52

Treatment Disease Clinical Trials Therapies 52

The Pharma Data

MARCH 8, 2021

“We are very pleased to share our initial Phase 2 infectivity data at this important conference, which remains at the forefront for critical clinical scientific information in infectious diseases,” shared Dr. Wendy Painter, Chief Medical Officer of Ridgeback Biotherapeutics. “At About Molnupiravir. About Ridgeback Biotherapeutics.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

JULY 12, 2021

The data were presented during the late-breaking clinical trials session at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). Headquartered in Miami, Florida, Ridgeback Biotherapeutics LP is a biotechnology company focused on emerging infectious diseases. About Ridgeback Biotherapeutics.

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52

The Pharma Data

MARCH 16, 2021

inhibitor belzutifan (pronounced bell-ZOO-ti-fan), a novel investigational candidate in Merck’s oncology pipeline, for the potential treatment of patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), not requiring immediate surgery. in patients with VHL disease-associated RCC.

FDA 52

FDA Disease Trials Drugs 52

The Pharma Data

SEPTEMBER 28, 2021

10) and who haven’t received prior chemotherapy for metastatic disease. Triple-negative carcinoma grows and spreads faster than other sorts of carcinoma and consequently features a worse prognosis,” said Dr. Vicki Goodman, vice chairman , clinical research, Merck Research Laboratories. Source link: [link].

Research Laboratories 52

Research Laboratories Clinical Research Treatment Disease 52

The Pharma Data

SEPTEMBER 1, 2021

Headquartered in Miami, Florida, Ridgeback Biotherapeutics LP is a biotechnology company focused on emerging infectious diseases. The team at Ridgeback is dedicated to working toward finding life-saving and life-changing solutions for patients and diseases that need champions. Data from the study is expected in the second half of 2021.

Laboratories 52

Laboratories Clinical Trials Virus Trials 52

Codon

JULY 21, 2024

Of course, AA and P-line rats are not the only research animals bred for the study of disease. The most famous of these is the Oncomouse , engineered in 1984 for the express purpose of developing tumors so that researchers could study cancer in living organisms, rather than in petri dishes. 1 Subscribe to Asimov Press.

Research 124

Research Engineering Disease Science 124

The Connected Lab

APRIL 29, 2020

For laboratories on the front line of the COVID-19 fight, time spent connecting instruments and software is time lost fighting the disease. When time is critical to the success of your laboratory’s mission, you need proven solutions that connect seamlessly and support your end-to-end workflow.

Laboratories 52

Laboratories Vaccine Research Laboratories Treatment 52

The Pharma Data

NOVEMBER 19, 2020

Gelbman most recently served as the founding CEO of FDNA, a digital health startup that develops advanced AI tools to help diagnose patients with rare diseases. Patel currently serves as the director of Infectious Diseases Research Laboratory at the Mayo Clinic, as well as co-director of the clinical Bacteriology Laboratory.

Laboratories 52

Laboratories Research Laboratories Science Organic Chemistry 52

The Pharma Data

OCTOBER 12, 2021

The winning research receives 5,000 USD and a bronze horse for the research that has the highest translational potential; the investigator is awarded with 1,000 USD and the research laboratory 4,000 USD to continue the great work. We develop solutions and provide services to protect animals from disease and pain.

Research Laboratories 52

Research Laboratories Laboratories Therapies Production 52

The Pharma Data

AUGUST 31, 2021

“While the treatment landscape has evolved, an unmet need remains for appropriate patients newly diagnosed with certain types of advanced urothelial carcinoma who are not eligible for platinum-containing chemotherapy,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. “We

FDA Approval 52

FDA Approval Treatment FDA Research Laboratories 52

The Pharma Data

MARCH 8, 2021

“We are delighted to share our early data at CROI 2021 supporting the potential for a once-yearly dosing regimen for islatravir using a subdermal implant,” said Dr. Joan Butterton, vice president, global clinical development, infectious diseases, Merck Research Laboratories. “We Our Commitment to Infectious Diseases.

Trials 52

Trials Clinical Trials Pharmacokinetics Research Laboratories 52

The Pharma Data

MARCH 17, 2021

KEYTRUDA reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.48-0.88]; Randomization was stratified by prior ASCT (yes vs. no) and disease status after frontline therapy (primary refractory vs. relapse less than 12 months after completion vs. relapse 12 months or more after completion). months versus 8.3

Therapies 52

Therapies Treatment Disease Trials 52

The Pharma Data

MARCH 15, 2022

“There remains a significant unmet need for patients diagnosed with advanced prostate cancer, who have a poor prognosis after not responding to initial therapy,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Source link: [link].

DNA 52

DNA Clinical Trials Trials Therapies 52

The Pharma Data

NOVEMBER 22, 2020

PAH is a chronic, progressive disease caused by the hardening and narrowing of the pulmonary arteries that can cause right heart failure and eventual death. The drug also received Rare Pediatric Disease Designation for these indications. It was granted Priority Review. with LEPR deficiency obesity. Featured Jobs on BioSpace.

FDA 52

FDA Licensing Licensing Treatment 52

The Pharma Data

AUGUST 7, 2020

The ARM report also showcased robust pipelines of therapies targeting indications in cancers, infectious diseases and inherited disorders. These manufactured antibodies have been developed and manufactured by Eli Lilly and Company ’s Lilly Research Laboratories in a partnership with AbCellera. Dr. Francis S.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

NIH Director's Blog: Drug Development

MARCH 11, 2014

Credit: Jane Ades, National Human Genome Research Institute, NIH Type 2 diabetes (T2D) tends to run in families, and over the last five years the application of genomic technologies has led to discovery of more than 60 specific DNA variants that contribute to risk. 2012;7(7):e40972. Link: Accelerating Medicines Partnership.

DNA 52

DNA Drugs Disease Research Laboratories 52

The Pharma Data

NOVEMBER 18, 2021

For over 130 years, Merck, known as MSD outside the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. Source link: [link].

Clinical Trials 52

Clinical Trials Treatment Trials RNA 52

The Pharma Data

JUNE 1, 2022

Under her leadership, Pfizer advanced into clinical development or approval bacterial vaccine programs directed at the prevention of diseases due to Streptococcus pneumoniae, Group B Streptococcus, Neisseria meningitidis, Staphylococcus aureus, and Clostridium difficile. Dr. Anderson joined Pfizer via Wyeth in 2007.

Vaccine 40

Vaccine Research Laboratories Doctors 40

The Pharma Data

MARCH 16, 2021

This collaboration with the Lieber Institute further expands our innovative neuropsychiatric research program, a key focus area at Boehringer Ingelheim, with a first-in-class mechanism that may have the potential to address these symptoms,” said Dr. Hugh Marston, Ph.D., Head of Department CNS Diseases Research at Boehringer Ingelheim. “By

Licensing 52

Licensing Licensing Research Laboratories Treatment 52

The Pharma Data

AUGUST 30, 2021

“We are pleased to offer two potential new treatment options with KEYTRUDA for patients in Japan based on compelling data from our clinical trial program,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. months (95% CI, 7.6-11.3) months (95% CI, 5.3-7.5),

Treatment 52

Treatment Trials Research Laboratories Clinical Trials 52

The Pharma Data

AUGUST 10, 2021

The FDA’s acceptance of our application adds to our momentum of advancing new treatment options to address the most challenging cancers facing women,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. In the U.S.,

FDA 52

FDA Therapies Treatment Clinical Research 52

The Pharma Data

OCTOBER 19, 2020

Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

JUNE 29, 2021

0.86]; p<0.0001) and reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.55-0.76]; 0.78]; p<0.0001) and reduced the risk of disease progression or death by 49% (HR=0.51 [95% CI, 0.41-0.65]; Patients could be treated with KEYTRUDA for up to 24 months in the absence of disease progression.

Therapies 52

Therapies Treatment Disease Clinical Research 52

The Pharma Data

JULY 21, 2021

“This announcement reflects another important regulatory milestone in the development of this medicine,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Forward-Looking Statement of Merck & Co., Kenilworth, N.J.,

Treatment 52

Treatment Production Disease FDA Approval 52

The Pharma Data

SEPTEMBER 7, 2021

“In China, esophageal and gastroesophageal junction cancers are leading causes of death, and there have been few treatment advances for patients over the past several decades,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. The median OS was 12.4 months (95% CI, 10.5-14.0)

Treatment 52

Treatment Research Laboratories Packaging Laboratories 52

The Pharma Data

JULY 21, 2021

For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. Forward-Looking Statement of Merck & Co., Kenilworth, N.J.,

Clinical Trials 52

Clinical Trials Pharmacokinetics Trials International 52

The Pharma Data

JUNE 2, 2023

Many patients with mCRPC are only able to receive one line of therapy, as the disease can progress quickly. In the U.S., prostate cancer is the second most common cancer in men, and despite an increase in the number of available therapies for patients with mCRPC, five-year survival remains low.

FDA Approval 52

FDA Approval FDA Therapies Treatment 52

Codon

DECEMBER 10, 2023

If you have protein libraries in your research laboratory, please send them to us (datasets@alignbio.org) for analysis. The biggest challenge will be to acquire DNA that encodes millions of different proteins. Synthesizing that much DNA is cost-prohibitive. We’ll analyze the proteins and provide you with expression data for free.

Protein Expression 103

Protein Expression Laboratories DNA Engineering 103